Gene · 8205
Papers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 2,064
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response. | Biochem Soc Trans | 2023 | 36938978 | PubTator, text mining | PubMed |
| Opportunities and challenges related to ferroptosis in glioma and neuroblastoma. | Front Oncol | 2023 | 36937406 | PubTator, text mining | PubMed |
| Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. | EClinicalMedicine | 2023 | 36936404 | PubTator, text mining | PubMed |
| Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. | JTO Clin Res Rep | 2023 | 36925644 | PubTator, text mining | PubMed |
| Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer. | BMC Gastroenterol | 2023 | 36918802 | PubTator, text mining | PubMed |
| CTHRC1 is associated with immune cell infiltration and functions as an adverse marker for prognosis in head and neck squamous cell carcinoma. | Oncol Lett | 2023 | 36909370 | PubTator, text mining | PubMed |
| Upregulation of APOC1 Promotes Colorectal Cancer Progression and Serves as a Potential Therapeutic Target Based on Bioinformatics Analysis. | J Oncol | 2023 | 36908705 | PubTator, text mining | PubMed |
| Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. | Mol Cancer | 2023 | 36906534 | PubTator, text mining | PubMed |
| Gut-Brain cross talk: The pathogenesis of neurodevelopmental impairment in necrotizing enterocolitis. | Front Pediatr | 2023 | 36873645 | PubTator, text mining | PubMed |
| GLUT10 is a novel immune regulator involved in lung cancer immune cell infiltration and predicts worse survival when transcriptionally downregulated. | Heliyon | 2023 | 36873535 | PubTator, text mining | PubMed |
| Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells. | J Mol Med (Berl) | 2023 | 36869893 | PubTator, text mining | PubMed |
| Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy. | Endocr Rev | 2023 | 36869790 | PubTator, text mining | PubMed |
| Identification of STAT5B as a biomarker associated with prognosis and immune infiltration in breast cancer. | Medicine (Baltimore) | 2023 | 36862902 | PubTator, text mining | PubMed |
| Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. | Cancer Commun (Lond) | 2023 | 36855844 | PubTator, text mining | PubMed |
| Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC. | Oncol Lett | 2023 | 36844625 | PubTator, text mining | PubMed |
| Local delivery of gaseous signaling molecules for orthopedic disease therapy. | J Nanobiotechnology | 2023 | 36810201 | PubTator, text mining | PubMed |
| SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. | J Immunother Cancer | 2023 | 36808075 | PubTator, text mining | PubMed |
| TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. | Aging (Albany NY) | 2023 | 36801818 | PubTator, text mining | PubMed |
| Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-𝜅B-IL-6 axis of tumor-associated macrophages. | J Exp Clin Cancer Res | 2023 | 36797769 | PubTator, text mining | PubMed |
| Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems. | Cancer Med | 2023 | 36794651 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8205/papers?page=22